Widely used:Recently Viewed
Clear All$2.38
$-0.03
(-1.24%)
As on 29-Apr-2025 16:00EDT
Today’s Range
52 Week Range
Liquidity
Market cap
$28 Mln
P/E Ratio
--
P/B Ratio
3.6
Industry P/E
--
Debt to Equity
0
ROE
-0.26 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
--
CFO
S$-8.03 Mln
EBITDA
S$-8.17 Mln
Net Profit
S$-12.23 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
CytoMed Therapeutics Limited Ordinary Shares (GDTC)
| -30.00 | 5.78 | -4.42 | 13.33 | -- | -- | -- |
|
BSE Sensex
| 2.61 | 3.71 | 5.78 | 8.89 | 11.76 | 20.11 | 11.35 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
|
|---|---|
|
CytoMed Therapeutics Limited Ordinary Shares (GDTC)
| -30.41 |
|
S&P Small-Cap 600
| 7.01 |
|
BSE Sensex
| 8.10 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is... CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company also has Business & Research Collaboration Agreement with SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore. Address: 1 Commonwealth Lane, No. 08-22, Singapore, Singapore, 149544 Read more
Executive Chairman
Mr. Chee Kong Choo
Executive Chairman
Mr. Chee Kong Choo
Headquarters
Singapore
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of CytoMed Therapeutics Limited Ordinary Shares (GDTC) stood at $ 14 Mln as on 30-Jun-24
The share price of CytoMed Therapeutics Limited Ordinary Shares (GDTC) is $2.38 (NASDAQ) as of 29-Apr-2025 16:00 EDT. CytoMed Therapeutics Limited Ordinary Shares (GDTC) has given a return of 13.33% in the last 1 years.
CytoMed Therapeutics Limited Ordinary Shares (GDTC) has a market capitalisation of $ 28 Mln as on 29-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of CytoMed Therapeutics Limited Ordinary Shares (GDTC) is 3.60 times as on 29-Apr-2025, a 57% premium to its peers’ median range of 2.29 times.
Since, TTM earnings of CytoMed Therapeutics Limited Ordinary Shares (GDTC) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the CytoMed Therapeutics Limited Ordinary Shares (GDTC) and enter the required number of quantities and click on buy to purchase the shares of CytoMed Therapeutics Limited Ordinary Shares (GDTC).
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company also has Business & Research Collaboration Agreement with SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore. Address: 1 Commonwealth Lane, No. 08-22, Singapore, Singapore, 149544
The CEO & director of Mr. Chee Kong Choo. is CytoMed Therapeutics Limited Ordinary Shares (GDTC), and CFO & Sr. VP is Mr. Chee Kong Choo.
There is no promoter pledging in CytoMed Therapeutics Limited Ordinary Shares (GDTC).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| CytoMed Therapeutics Limited Ordinary Shares (GDTC) | Ratios |
|---|---|
|
Return on equity(%)
|
-36.24
|
|
Operating margin(%)
|
-2186.2
|
|
Net Margin(%)
|
-2060.38
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of CytoMed Therapeutics Limited Ordinary Shares (GDTC) was $0 Mln.
